Abstract
Vasculogenic mimicry (VM) is the biological process by which aggressive cancer cells are able to organize themselves—independently from endothelial cells—into new vessel-like structures to sustain fast tumor perfusion and thus an efficient supply of oxygen and nutrients, required for rapid cancer growth and dissemination. In the last two decades, the molecular mechanisms and key regulators of VM have been identified. Several methods are currently available to detect VM both in vitro and in vivo, but the gold standard is still the immunohistochemical staining of specific antigens. Even though many markers are debated if belong to the angiogenic process or VM exclusively, the immunohistochemistry of CD31 and the PAS reaction often clarify in frozen or paraffin sections the pathologic status and the vasculature grade of a tumor mass.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10:417–427. https://doi.org/10.1038/nrd3455
Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307. https://doi.org/10.1038/nature10144
Luo Q, Wang J, Zhao W et al (2020) Vasculogenic mimicry in carcinogenesis and clinical applications. J Hematol Oncol 13:1–19. https://doi.org/10.1186/s13045-020-00858-6
Maniotis AJ, Folberg R, Hess A et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155:739–752. https://doi.org/10.1016/S0002-9440(10)65173-5
Delgado-Bellido D, Serrano-Saenz S, Fernández-Cortés M et al (2017) Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin. Mol Cancer. https://doi.org/10.1186/s12943-017-0631-x
Yang J, Zhu DM, Zhou XG et al (2017) HIF-2α promotes the formation of vasculogenic mimicry in pancreatic cancer by regulating the binding of Twist1 to the VE-cadherin promoter. Oncotarget 8:47801–47815. https://doi.org/10.18632/oncotarget.17999
Li M, Gu Y, Zhang Z et al (2010) Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res 16:259–266. https://doi.org/10.1007/s12253-009-9220-7
Baeten CIM, Hillen F, Pauwels P et al (2009) Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum 52:2028–2035. https://doi.org/10.1007/DCR.0b013e3181beb4ff
Seftor RE, Seftor EA, Koshikawa N et al (2001) Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 61:6322–6327
Seftor EA, Meltzer PS, Schatteman GC et al (2002) Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol 44:17–27. https://doi.org/10.1016/s1040-8428(01)00199-8
Maniotis AJ, Chen X, Garcia C et al (2002) Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. Lab Investig 82:1031–1043. https://doi.org/10.1097/01.lab.0000024362.12721.67
Zhang X, Zhang J, Zhou H et al (2019) Molecular mechanisms and anticancer therapeutic strategies in vasculogenic mimicry. J Cancer 10:6327–6340. https://doi.org/10.7150/jca.34171
Andreucci E, Laurenzana A, Peppicelli S et al (2021) uPAR controls vasculogenic mimicry ability expressed by drug-resistant melanoma cells. Oncol Res. https://doi.org/10.3727/096504021X16273798026651
Peri S, Biagioni A, Versienti G et al (2021) Enhanced vasculogenic capacity induced by 5-fluorouracil chemoresistance in a gastric cancer cell line. Int J Mol Sci 22(14):7698. https://doi.org/10.3390/ijms22147698
Yang Z, Yao H, Fei F et al (2018) Generation of erythroid cells from polyploid giant cancer cells: re-thinking about tumor blood supply. J Cancer Res Clin Oncol 144:617–627. https://doi.org/10.1007/s00432-018-2598-4
Ge H, Luo H (2018) Overview of advances in vasculogenic mimicry – a potential target for tumor therapy. CMAR 10:2429–2437. https://doi.org/10.2147/CMAR.S164675
Cao Z, Bao M, Miele L et al (2013) Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer 49:3914–3923. https://doi.org/10.1016/j.ejca.2013.07.148
Topczewska JM, Postovit LM, Margaryan NV et al (2006) Embryonic and tumorigenic pathways converge via nodal signaling: role in melanoma aggressiveness. Nat Med 12:925–932. https://doi.org/10.1038/nm1448
Andonegui-Elguera MA, Alfaro-Mora Y, Cáceres-Gutiérrez R et al (2020) An overview of vasculogenic mimicry in breast cancer. Front Oncol. https://doi.org/10.3389/fonc.2020.00220
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Biagioni, A., Andreucci, E. (2022). Immunohistochemistry for VM Markers. In: Marques dos Reis, E., Berti, F. (eds) Vasculogenic Mimicry. Methods in Molecular Biology, vol 2514. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2403-6_14
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2403-6_14
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2402-9
Online ISBN: 978-1-0716-2403-6
eBook Packages: Springer Protocols